Editorial
Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib
Translational Lung Cancer Research
2019;
8
(4)
:317-318
.
(31 August 2019)
Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?
Translational Lung Cancer Research
2019;
8
(4)
:319-322
.
(31 August 2019)
Original Article
Presence of intra-tumoral CD61+ megakaryocytes predicts poor prognosis in non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(4)
:323-331
.
(31 August 2019)
Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(4)
:332-339
.
(31 August 2019)
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
Translational Lung Cancer Research
2019;
8
(4)
:340-351
.
(31 August 2019)
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Translational Lung Cancer Research
2019;
8
(4)
:352-366
.
(31 August 2019)
Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study
Translational Lung Cancer Research
2019;
8
(4)
:367-379
.
(31 August 2019)
Exploring barriers to lung cancer patient access, diagnosis, referral and treatment in Kwazulu-Natal, South Africa: the health providers’ perspectives
Translational Lung Cancer Research
2019;
8
(4)
:380-391
.
(31 August 2019)
Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma
Translational Lung Cancer Research
2019;
8
(4)
:392-400
.
(31 August 2019)
Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study
Translational Lung Cancer Research
2019;
8
(4)
:401-412
.
(31 August 2019)
The association of PD-L1 expression with the efficacy of anti- PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Translational Lung Cancer Research
2019;
8
(4)
:413-428
.
(31 August 2019)
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients
Translational Lung Cancer Research
2019;
8
(4)
:429-449
.
(31 August 2019)
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients
Translational Lung Cancer Research
2019;
8
(4)
:450-460
.
(31 August 2019)
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
Translational Lung Cancer Research
2019;
8
(4)
:461-475
.
(31 August 2019)
MUC16 in non-small cell lung cancer patients affected by familial lung cancer and indoor air pollution: clinical characteristics and cell behaviors
Translational Lung Cancer Research
2019;
8
(4)
:476-488
.
(31 August 2019)
Metabolic profiles of serum samples from ground glass opacity represent potential diagnostic biomarkers for lung cancer
Translational Lung Cancer Research
2019;
8
(4)
:489-499
.
(31 August 2019)
Influence and mechanism of lung cavitation development on antiangiogenic therapy
Translational Lung Cancer Research
2019;
8
(4)
:500-512
.
(31 August 2019)
Brief Report
Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite non-malignant cytology
Translational Lung Cancer Research
2019;
8
(4)
:513-518
.
(31 August 2019)
Study Protocol
Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)
Translational Lung Cancer Research
2019;
8
(4)
:519-523
.
(31 August 2019)
Review Article
Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions
Translational Lung Cancer Research
2019;
8
(4)
:524-531
.
(31 August 2019)
Case Report
Effective targeted therapy based on dynamic monitoring of gene mutations in non-small cell lung cancer
Translational Lung Cancer Research
2019;
8
(4)
:532-538
.
(31 August 2019)
Editorial Commentary
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2019;
8
(4)
:539-542
.
(31 August 2019)
Sex disparities in lung cancer incidence: validation of a long-observed trend
Translational Lung Cancer Research
2019;
8
(4)
:543-545
.
(31 August 2019)
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?
Translational Lung Cancer Research
2019;
8
(4)
:546-549
.
(31 August 2019)
Osimertinib in first line setting: for Asian patients
Translational Lung Cancer Research
2019;
8
(4)
:550-552
.
(31 August 2019)
Measuring tumor mutation burden in cell-free DNA: advantages and limits
Translational Lung Cancer Research
2019;
8
(4)
:553-555
.
(31 August 2019)
News
The first attempt worldwide to test PD-1 antibody on multiple “Stage 0” lung cancer
Translational Lung Cancer Research
2019;
8
(4)
:556-557
.
(31 August 2019)
Erratum
Erratum: Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine
Translational Lung Cancer Research
2019;
8
(4)
:558
.
(31 August 2019)
